Biomarkers in Cancer Screening and Early Detection

Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state–of–the–art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and clinical use. The primary purpose of this book is to summarize and present best practices in this field to date, and offer actionable information and hopefully also inspiration to move discovery and clinical application forward.

This latest volume of the Translational Oncology series, Biomarkers in Cancer Screening and Early Detection is organized into three sections: Section I lays the foundation for biomarker discovery, development and validation. Section II presents organ–specific topics relevant to the clinical needs in early detection, the natural history of the disease and associated evidence in support of biomarker research, an overview of the current state–of–the art in biomarker research, current progress toward bringing these biomarkers into clinical use and the future of biomarker–based screening and early detection for the respective organ type. Finally, Section III offers chapters that address the current screening strategies for selected organ types, discuss deficiencies with the present practice and identify clinical needs that may benefit from biomarker–based approaches.

Sudhir Srivastava, Ph.D., MPH

Senior Scientific Officer, Chief, Cancer Biomarkers Research Group

Division of Cancer Prevention, National Cancer Institute

Bethesda, MD, USA

Dr Srivastava has received many honors and awards and is a member of several scientific committees (AJCC, AACR, All Ireland–NCI Consortium). Dr. Srivastava is a founding member of HUPO (Human Proteome Organisation) and has actively participated in the Plasma Proteome and the Liver Proteome Projects. He is the principal architect of the NCI s Early Detection Research Network and Alliance of Glycobiologists for the Detection of Cancer and Cancer Risk. He supported the first–ever joint meetings of EDRN–HUPO PPP and Proteomics Jamboree, and recently–held the US–Japan meeting on Glycolic. He has published more than 200 research papers, review articles and commentaries in peer reviewed journals. HJ has edited two other books: Informatics in Proteomics and Nanotechnology for Cancer Detection and Diagnosis (forthcoming). He is also the Editor–in Chief of the journals Disease Markers and Cancer Biomarkers.